Xilio Therapeutics Inc (NAS:XLO)
$ 1.02 -0.02 (-1.92%) Market Cap: 44.84 Mil Enterprise Value: -7.13 Mil PE Ratio: 0 PB Ratio: 2.18 GF Score: 27/100

Xilio Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript

Apr 13, 2022 / 12:00PM GMT
Release Date Price: $6.73 (-2.89%)
Chang Liu
Needham & Company, LLC - Analyst

Good morning and welcome to the 21st Needham healthcare conference. My name is Chang Liu, and I will be the moderator for this presentation. It is our pleasure to have Xilio Therapeutics here today and its CMO, Martin Huber. (Conference Instructions)

Without further ado, Martin, would you like to start your presentation?

Martin Huber
Xilio Therapeutics, Inc. - President of R&D & Chief Medical Officer

Thank you, Chang. Good morning. I'm Martin Huber; I'm the President of R&D and Chief Medical Officer at Xilio Therapeutics.

Just by way a quick introduction, I've been with Xilio now for about two years. Prior to that, I was the Chief Medical Officer at Tesaro. You may recall, we had July -- as well as three I-O agents. Prior to that, I was the Merck Keytruda lung cancer program lead for the initial filings in lung cancer. And I've held multiple jobs in the industry. I'm a medical oncologist by training out of the M.D. Anderson Cancer Center.

So what I'd like to share with

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot